A Cost Effectiveness and Capacity Analysis for the Introduction of Universal Rotavirus Vaccination in Kenya: Comparison between Rotarix and RotaTeq Vaccines
Authors:
Open Access
- 24 October 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (10) , e47511
Abstract
Diarrhoea is an important cause of death in the developing world, and rotavirus is the single most important cause of diarrhoea associated mortality. Two vaccines (Rotarix and RotaTeq) are available to prevent rotavirus disease. This analysis was undertaken to aid the decision in Kenya as to which vaccine to choose when introducing rotavirus vaccination. Cost-effectiveness modelling, using national and sentinel surveillance data, and an impact assessment on the cold chain. The median estimated incidence of rotavirus disease in Kenya was 3015 outpatient visits, 279 hospitalisations and 65 deaths per 100,000 children under five years of age per year. Cumulated over the first five years of life vaccination was predicted to prevent 34% of the outpatient visits, 31% of the hospitalizations and 42% of the deaths. The estimated prevented costs accumulated over five years totalled US$1,782,761 (direct and indirect costs) with an associated 48,585 DALYs. From a societal perspective Rotarix had a cost-effectiveness ratio of US$142 per DALY (US$5 for the full course of two doses) and RotaTeq US$288 per DALY ($10.5 for the full course of three doses). RotaTeq will have a bigger impact on the cold chain compared to Rotarix. Vaccination against rotavirus disease is cost-effective for Kenya irrespective of the vaccine. Of the two vaccines Rotarix was the preferred choice due to a better cost-effectiveness ratio, the presence of a vaccine vial monitor, the requirement of fewer doses and less storage space, and proven thermo-stability.Keywords
This publication has 25 references indexed in Scilit:
- Basing care reforms on evidence: The Kenya health sector costing modelBMC Health Services Research, 2011
- Children who were vaccinated, breast fed and from low parity mothers live longer: A community based case-control study in Jimma, EthiopiaBMC Public Health, 2011
- Rotavirus vaccine and diarrhea mortality: quantifying regional variation in effect sizeBMC Public Health, 2011
- Rotavirus Genetic Diversity, Disease Association, and Temporal Change in Hospitalized Rural Kenyan ChildrenThe Journal of Infectious Diseases, 2010
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trialThe Lancet, 2010
- Global, regional, and national causes of child mortality in 2008: a systematic analysisThe Lancet, 2010
- Rotavirus Disease Burden and Impact and Cost‐Effectiveness of a Rotavirus Vaccination Program in KenyaThe Journal of Infectious Diseases, 2009
- Oral Rotavirus Vaccines: How Well Will They Work Where They Are Needed Most?The Journal of Infectious Diseases, 2009
- Incidence and Clinical Characteristics of Group A Rotavirus Infections among Children Admitted to Hospital in Kilifi, KenyaPLOS Medicine, 2008